These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 16359345

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Pharmacogenomical aspects of gastroesophageal reflux disease].
    Isaev VA.
    Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
    [Abstract] [Full Text] [Related]

  • 5. Recurrent anaphylaxis linked to pantoprazole.
    Kollmeier AP, Eddleston J, Zuraw BL, Christiansen SC.
    J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
    [No Abstract] [Full Text] [Related]

  • 6. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T.
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
    Sugimoto M, Furuta T, Nakmura A, Shirai N.
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
    [No Abstract] [Full Text] [Related]

  • 9. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 12. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 13. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
    Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Cause and prevention of nocturnal gastric acid breakthrough].
    Adachi K, Kinoshita Y.
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
    Savarino V, Savarino E, Dulbecco P.
    Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.